Abstract
Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 100831-100851 |
| Number of pages | 21 |
| Journal | Oncotarget |
| Volume | 8 |
| Issue number | 59 |
| DOIs | |
| Publication status | Published - Aug 3 2017 |
Fingerprint
Keywords
- Biomarkers
- Blood serum
- Liquid biopsy
- Osteosarcoma
- Personalized medicine
ASJC Scopus subject areas
- Oncology
Cite this
Circulating biomarkers in osteosarcoma : New translational tools for diagnosis and treatment. / Raimondi, Lavinia; De Luca, Angela; Costa, Viviana; Amodio, Nicola; Carina, Valeria; Bellavia, Daniele; Tassone, Pierfrancesco; Pagani, Stefania; Fini, Milena; Alessandro, Riccardo; Giavaresi, Gianluca.
In: Oncotarget, Vol. 8, No. 59, 03.08.2017, p. 100831-100851.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Circulating biomarkers in osteosarcoma
T2 - New translational tools for diagnosis and treatment
AU - Raimondi, Lavinia
AU - De Luca, Angela
AU - Costa, Viviana
AU - Amodio, Nicola
AU - Carina, Valeria
AU - Bellavia, Daniele
AU - Tassone, Pierfrancesco
AU - Pagani, Stefania
AU - Fini, Milena
AU - Alessandro, Riccardo
AU - Giavaresi, Gianluca
PY - 2017/8/3
Y1 - 2017/8/3
N2 - Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.
AB - Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.
KW - Biomarkers
KW - Blood serum
KW - Liquid biopsy
KW - Osteosarcoma
KW - Personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85034651700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034651700&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.19852
DO - 10.18632/oncotarget.19852
M3 - Review article
AN - SCOPUS:85034651700
VL - 8
SP - 100831
EP - 100851
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 59
ER -